GSK3B and Alzheimer disease: In this proof-of-concept study, we took advantage of an existing panel of dual GSK-3β/HDAC inhibitor candidates generated for the treatment of AD and demonstrated that these compounds could reduce the growth of Mtb inside human macrophages.